Become a fan of Slashdot on Facebook


Forgot your password?

Submission Interview With Julian Assange of Wikileaks

eldavojohn writes: A few months ago, I got in contact with an administrator at Wikileaks named Julian Assange. He agreed to a Slashdot interview and can be reached by e-mailing his first name at if Slashdot wishes to interview him. You can find interviews with him for more information on Wikileaks (and to avoid redundant questions). He has also coauthored a book called Underground: Tales of Hacking, Madness, and Obsession on the Electronic Frontier with Suelette Dreyfus that is available for free (gratis) electronically at Project Gutenberg. From Mormans to J.P. Morgan, Wikileaks has been distributing sensitive information (and making Slashdot headlines with it) with the consequences of lawsuits and litigation. I propose the Slashdot editors take him up on his offer for an interview here at Slashdot. Given the recent claims of harassment by the United States government, I would wager we could drum up some good questions.

Comment The only thing it obsoleted: (Score 1) 778

Was payphones, i can think of plenty of reasons to have separate versions of each one. Point and shoots still run circles around anything a cellphone can do. It's still a question of lens size/image sensor. The big thing with these all-in-one phones, is that when your cellphone breaks or encounters a problem, everything breaks. That and when better components come out (mp3s, cameras) happen, you don't need to worry about upgrading everything or being left behind.

Submission SPAM: Man's own cells killing his skin cancer 1

Roland Piquepaille writes: "As you probably know, melanoma is one of the deadliest forms of skin cancer, usually caused by too much exposure to the sun. Now U.S. researchers have developed a way to use a patient's own cloned T-cells against this skin cancer — without chemotherapy or radiation. For example, 'a 52-year-old man whose Stage 4 melanoma had spread to a groin lymph node and to a lung,' is now tumor-free two years after being treated by 'immunotherapy.' Even if these results are encouraging, 'more studies are needed to confirm the effectiveness of the experimental T-cell therapy.' But read more for additional details and references about this advance in cancer fighting."

We warn the reader in advance that the proof presented here depends on a clever but highly unmotivated trick. -- Howard Anton, "Elementary Linear Algebra"